HCPCS J9000: Doxorubicin Hydrochloride Injection, 10 mg
Commercial payers pay $5 on average nationally for this procedure.
HCPCS Level II code J9000 describes an injection of doxorubicin hydrochloride, 10 mg, an antineoplastic chemotherapy agent typically administered as an intravenous chemotherapy infusion for treatment of malignant neoplasms; the service is generally provided in oncology outpatient infusion centers or hospital outpatient departments.
Customize your policy alerts
Sign up for hcpcs J9000 policy alerts
Get alerted when payer policies referencing J9000 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for J9000 cluster around BUCA’s average commercial benchmark of $5.3, with notable variation among major carriers. Blue Cross Blue Shield shows a relatively tight interquartile spread (P75–P25 = $1.8), and UnitedHealth Group is also compact (spread = $1.2), indicating concentration near their medians. Aetna and Cigna display wider dispersion driven by higher upper tails; Aetna’s interquartile spread is $2.4 while Cigna’s is $1.0, but Aetna’s maximum rate ($92.9) and Cigna’s high maximum ($66.0) create broader overall variability beyond the IQRs.
Comparing central tendencies, most payers cluster near BUCA’s mean of $5.3 and Cigna and Aetna share median values at $3.0, whereas Blue Cross Blue Shield and UnitedHealth Group medians are slightly higher at $4.5 and $3.2 respectively. The tightest IQRs belong to UnitedHealth Group and Blue Cross Blue Shield, while Aetna exhibits the widest overall dispersion when considering its extreme maximum.